Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma

Margaret A Fischl, S. E. Krown, K. P. O'Boyle, R. Mitsuyasu, S. Miles, J. C. Wernz, P. A. Volberding, J. Kahn, J. E. Groopman, J. Feinberg, M. Woody

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Fifty-three patients with AIDS-related Kaposi's sarcoma and no previous treatment with cytotoxic chemotherapy enrolled in a phase II multicenter study to evaluate the safety and efficacy of weekly doxorubicin treatment. Doxorubicin was given intravenously at a dose of 15 mg/m2. Patients were stratified for purposes of analyses by tumor burden and coexistence of HIV-associated signs and symptoms; stratum I included patients with cutaneous disease alone and no symptoms, and stratum II included patients with visceral disease, tumor-associated edema, a previous opportunistic infection, or systemic symptoms. Fifty-one patients were evaluable for toxicity and 50 for tumor response. Five patients had a partial response (10%); 32, a minor response (64%); 12, no change (24%); and one, progression (2%) as the best measurable response. Partial response durations ranged from 4 to 14 weeks. Fifteen patients subsequently showed progression while on treatment. A significantly greater number of patients in stratum I (20.1%) had a partial response compared with those in stratum II (0%, p = 0.009). The major toxicities included nausea (37%), stomatitis (9.8%), mucositis (13.7%), and moderate to severe neutropenia (71%). Neutropenia was dose limiting and resulted in discontinuation of doxorubicin in 18% of the patients. Two patients developed cardiac toxicity. In conclusion, doxorubicin treatment induced relatively few tumor responses and remission durations were short. Treatment was limited by a high rate of toxicity.

Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume6
Issue number3
StatePublished - Jan 1 1993

Fingerprint

Doxorubicin
Therapeutics
Neutropenia
AIDS-related Kaposi sarcoma
Neoplasms
Stomatitis
Mucositis
Opportunistic Infections
Tumor Burden
Skin Diseases
Nausea
Multicenter Studies
Signs and Symptoms
Edema
HIV
Safety
Drug Therapy

ASJC Scopus subject areas

  • Virology
  • Immunology and Allergy

Cite this

Fischl, M. A., Krown, S. E., O'Boyle, K. P., Mitsuyasu, R., Miles, S., Wernz, J. C., ... Woody, M. (1993). Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. Journal of Acquired Immune Deficiency Syndromes, 6(3), 259-264.

Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. / Fischl, Margaret A; Krown, S. E.; O'Boyle, K. P.; Mitsuyasu, R.; Miles, S.; Wernz, J. C.; Volberding, P. A.; Kahn, J.; Groopman, J. E.; Feinberg, J.; Woody, M.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 6, No. 3, 01.01.1993, p. 259-264.

Research output: Contribution to journalArticle

Fischl, MA, Krown, SE, O'Boyle, KP, Mitsuyasu, R, Miles, S, Wernz, JC, Volberding, PA, Kahn, J, Groopman, JE, Feinberg, J & Woody, M 1993, 'Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma', Journal of Acquired Immune Deficiency Syndromes, vol. 6, no. 3, pp. 259-264.
Fischl, Margaret A ; Krown, S. E. ; O'Boyle, K. P. ; Mitsuyasu, R. ; Miles, S. ; Wernz, J. C. ; Volberding, P. A. ; Kahn, J. ; Groopman, J. E. ; Feinberg, J. ; Woody, M. / Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. In: Journal of Acquired Immune Deficiency Syndromes. 1993 ; Vol. 6, No. 3. pp. 259-264.
@article{ea844afc9ef14e8c8764a1aca88d8f1b,
title = "Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma",
abstract = "Fifty-three patients with AIDS-related Kaposi's sarcoma and no previous treatment with cytotoxic chemotherapy enrolled in a phase II multicenter study to evaluate the safety and efficacy of weekly doxorubicin treatment. Doxorubicin was given intravenously at a dose of 15 mg/m2. Patients were stratified for purposes of analyses by tumor burden and coexistence of HIV-associated signs and symptoms; stratum I included patients with cutaneous disease alone and no symptoms, and stratum II included patients with visceral disease, tumor-associated edema, a previous opportunistic infection, or systemic symptoms. Fifty-one patients were evaluable for toxicity and 50 for tumor response. Five patients had a partial response (10{\%}); 32, a minor response (64{\%}); 12, no change (24{\%}); and one, progression (2{\%}) as the best measurable response. Partial response durations ranged from 4 to 14 weeks. Fifteen patients subsequently showed progression while on treatment. A significantly greater number of patients in stratum I (20.1{\%}) had a partial response compared with those in stratum II (0{\%}, p = 0.009). The major toxicities included nausea (37{\%}), stomatitis (9.8{\%}), mucositis (13.7{\%}), and moderate to severe neutropenia (71{\%}). Neutropenia was dose limiting and resulted in discontinuation of doxorubicin in 18{\%} of the patients. Two patients developed cardiac toxicity. In conclusion, doxorubicin treatment induced relatively few tumor responses and remission durations were short. Treatment was limited by a high rate of toxicity.",
author = "Fischl, {Margaret A} and Krown, {S. E.} and O'Boyle, {K. P.} and R. Mitsuyasu and S. Miles and Wernz, {J. C.} and Volberding, {P. A.} and J. Kahn and Groopman, {J. E.} and J. Feinberg and M. Woody",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "259--264",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "3",

}

TY - JOUR

T1 - Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma

AU - Fischl, Margaret A

AU - Krown, S. E.

AU - O'Boyle, K. P.

AU - Mitsuyasu, R.

AU - Miles, S.

AU - Wernz, J. C.

AU - Volberding, P. A.

AU - Kahn, J.

AU - Groopman, J. E.

AU - Feinberg, J.

AU - Woody, M.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Fifty-three patients with AIDS-related Kaposi's sarcoma and no previous treatment with cytotoxic chemotherapy enrolled in a phase II multicenter study to evaluate the safety and efficacy of weekly doxorubicin treatment. Doxorubicin was given intravenously at a dose of 15 mg/m2. Patients were stratified for purposes of analyses by tumor burden and coexistence of HIV-associated signs and symptoms; stratum I included patients with cutaneous disease alone and no symptoms, and stratum II included patients with visceral disease, tumor-associated edema, a previous opportunistic infection, or systemic symptoms. Fifty-one patients were evaluable for toxicity and 50 for tumor response. Five patients had a partial response (10%); 32, a minor response (64%); 12, no change (24%); and one, progression (2%) as the best measurable response. Partial response durations ranged from 4 to 14 weeks. Fifteen patients subsequently showed progression while on treatment. A significantly greater number of patients in stratum I (20.1%) had a partial response compared with those in stratum II (0%, p = 0.009). The major toxicities included nausea (37%), stomatitis (9.8%), mucositis (13.7%), and moderate to severe neutropenia (71%). Neutropenia was dose limiting and resulted in discontinuation of doxorubicin in 18% of the patients. Two patients developed cardiac toxicity. In conclusion, doxorubicin treatment induced relatively few tumor responses and remission durations were short. Treatment was limited by a high rate of toxicity.

AB - Fifty-three patients with AIDS-related Kaposi's sarcoma and no previous treatment with cytotoxic chemotherapy enrolled in a phase II multicenter study to evaluate the safety and efficacy of weekly doxorubicin treatment. Doxorubicin was given intravenously at a dose of 15 mg/m2. Patients were stratified for purposes of analyses by tumor burden and coexistence of HIV-associated signs and symptoms; stratum I included patients with cutaneous disease alone and no symptoms, and stratum II included patients with visceral disease, tumor-associated edema, a previous opportunistic infection, or systemic symptoms. Fifty-one patients were evaluable for toxicity and 50 for tumor response. Five patients had a partial response (10%); 32, a minor response (64%); 12, no change (24%); and one, progression (2%) as the best measurable response. Partial response durations ranged from 4 to 14 weeks. Fifteen patients subsequently showed progression while on treatment. A significantly greater number of patients in stratum I (20.1%) had a partial response compared with those in stratum II (0%, p = 0.009). The major toxicities included nausea (37%), stomatitis (9.8%), mucositis (13.7%), and moderate to severe neutropenia (71%). Neutropenia was dose limiting and resulted in discontinuation of doxorubicin in 18% of the patients. Two patients developed cardiac toxicity. In conclusion, doxorubicin treatment induced relatively few tumor responses and remission durations were short. Treatment was limited by a high rate of toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0027469683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027469683&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 259

EP - 264

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 3

ER -